Repurposing as a strategy in the fight against COVID-19

Testing existing drugs for additional indications is a promising approach to find drugs for COVID-19 patients as quickly as possible. For this purpose we use the Fraunhofer ITMP Repurposing Collection.

more info

Fraunhofer vs. Corona

Find out how Fraunhofer experts are contributing to the fight against the pandemic.

more info

Health Research in 4D

Fraunhofer ITMP conducts health research in line with the Fraunhofer 4D-Concept.

Fraunhofer CIMD

Fraunhofer ITMP is a core institute of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases.

more info

Research Divisions

Fraunhofer ITMP is organized in 3 cross-site research divisions.


Drug Discovery


From target to screening to lead optimization and formulation.


Preclinical Research


From translational target- and drug-validation to retranslational OMICs-analyses of patient samples for characterization of biological processes and identification of novel targets.


Clinical Research


From early „Proof-of-Concept“ to the characterization of approved products: “Quality by Design” as key to successful translation of innovative ideas to the patient.

Innovation Areas

Fraunhofer ITMP is optimally interconnected internally as well as externally with other Fraunhofer institutes, universities and industry via the innovation areas. This is the prerequisite for transdisciplinary and flexible cooperation in the areas of new technologies, disease and treatment concepts.



Further Notifications

Here you find all press releases and further notifications, as well as all events of Fraunhofer ITMP.

News / 26.4.2021

iCAIR® delivers first results in the fight against Sars-CoV-2


Fraunhofer ITMP is a temporary project partner for the additional research project focussing on the development of inhalable drugs to combat SARS-CoV-2, started in May 2020 within the frame of the international iCAIR® consortium. The iCAIR® research team, coordinated by Fraunhofer ITEM, can already report promising results for this project.

Press Release / 12.2.2021

State of Hesse funds Frankfurt biomedicine cluster ENABLE


Addressing intracellular signal transduction disorders caused by viral or bacterial infections, and the therapy of inflammatory diseases are the main goals of the Frankfurt biomedicine cluster ENABLE, in which Fraunhofer ITMP is also involved. The Hessian state government will fund this project for four years with a total of eight million euros in order to prepare it successfully for the next round of the federal and state excellence strategy.

Press Release / 9.2.2021

Fraunhofer ITMP successful in “Clusters4Future” competition


The PROXIDRUGS project was selected as part of the “Clusters4Future” competition by the German Federal Ministry of Education and Research (BMBF) and is funded with up to 15 million euros. In this project, Fraunhofer ITMP, together with seven regional partners under the leadership of the Goethe University Frankfurt am Main, is developing a novel class of active agents for the therapy of infectious, immune and neurodegenerative diseases.

Press Release / 19.1.2021

Fraunhofer ITMP seeks new treatments for rare childhood diseases


The European Joint Programme on Rare Diseases (EJP-RD) will fund two newly established European consortia with participation of Fraunhofer ITMP called CureMILS and TreatKCNQ with a total of over 3.6 million euros. The aim of the research project is to develop therapies against two rare diseases in children.

Press Release / 7.1.2021

Establishment of Fraunhofer ITMP


In recent years, the TMP branch of Fraunhofer Institute for Molecular Biology and Applied Ecology IME, based on its extensive expertise in the field of drug re-search and development, has become an increasingly important part of Fraunhofer’s health research efforts.

This development is now reflected in the establishment of the independent Fraunhofer Institute for Translational Medicine and Pharmacology ITMP with headquarters in Frankfurt am Main and locations in Hamburg and Göttingen as of January 1, 2021.